What is the half-life of Ativan (Lorazepam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. The half-life of Ativan (Lorazepam) is 12 hours for unconjugated lorazepam and 18 hours for its major metabolite, lorazepam glucuronide 1.

  • The half-life of the active form of the drug, unconjugated lorazepam, is the primary consideration for clinical use.
  • Key points to consider are the pharmacokinetics and metabolism of the drug.

From the Research

Half-Life of Ativan (Lorazepam)

The half-life of Ativan (Lorazepam) is reported to vary across different studies.

  • Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours 2
  • Values of elimination half-life (t1/2beta) in the elderly (15.9 hr) did not differ significantly from those in the young group (14.1 hr) 3
  • Variable half-lives were found (range 9.3-32.1 h, mean about 20 h) 4
  • The apparent elimination half-life of lorazepam was about 12 hr 5
  • Lorazepam can be classified as an intermediate-acting benzodiazepine, with a half-life value between 5-24 hours 6

Factors Influencing Half-Life

Several factors can influence the half-life of lorazepam, including:

  • Age: lorazepam clearance is somewhat reduced in old age 2, but age differences in lorazepam clearance were partly explained by more frequent cigarette smoking in the young subjects 3
  • Liver disease: liver disease has a minimal effect on lorazepam clearance 2, but may impair clearance in long-acting benzodiazepines 6
  • Renal disease: renal disease is associated with a prolonged half-life and increased volume of distribution of oxazepam, but its effect on lorazepam is not well-studied 2

References

Research

Clinical pharmacokinetics of oxazepam and lorazepam.

Clinical pharmacokinetics, 1981

Research

Lorazepam kinetics in the elderly.

Clinical pharmacology and therapeutics, 1979

Research

Benzodiazepines: a summary of pharmacokinetic properties.

British journal of clinical pharmacology, 1981

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.